Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.32 | 1.93 |
NAV | ₹30.39 | ₹426.87 |
Fund Started | 20 Jun 2019 | 04 Jun 1999 |
Fund Size | ₹814.18 Cr | ₹3689.28 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 11.40% | 21.35% |
3 Year | 22.48% | 28.36% |
5 Year | 19.39% | 24.20% |
1 Year
3 Year
5 Year
Equity | 97.94% | 96.09% |
Cash | 2.06% | 3.83% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.08% |
Cipla Ltd. | 7.69% |
Apollo Hospitals Enterprise Ltd. | 7.18% |
Abbott India Ltd. | 6.09% |
Torrent Pharmaceuticals Ltd. | 5.47% |
Lupin Ltd. | 4.72% |
Fortis Healthcare Ltd. | 4.58% |
Ajanta Pharma Ltd. | 3.99% |
Ipca Laboratories Ltd. | 3.85% |
Aurobindo Pharma Ltd. | 3.82% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.73% |
Divi's Laboratories Ltd. | 7.39% |
Max Healthcare Institute Ltd. | 6.40% |
Lonza Group Ag | 4.81% |
Cipla Ltd. | 4.77% |
Lupin Ltd. | 4.46% |
Mankind Pharma Ltd. | 3.75% |
Krishna Institute of Medical Sciences Ltd | 3.34% |
Fortis Healthcare Ltd. | 3.22% |
Acutaas Chemicals Ltd. | 3.19% |
Name | Dhaval Joshi | Tanmaya Desai |
Start Date | 21 Nov 2022 | 27 Jun 2011 |
Name
Start Date
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 20 Jun 2019 | 04 Jun 1999 |
Description
Launch Date